News
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy. The study — published May 11 in the New England Journal of Medicine — followed 751 people across the U.
GLP-1 drugs achieve some of these effects by directly affecting the brain’s cravings for food, and that might also extend to ...
The best metric is not weight, but a particularly toxic kind of fat.
First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...
A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...
Former FDA Commissioner David Kessler shared his experience with GLP-1 weight loss drugs on "CBS Mornings Plus." ...
GLP-1 medications like semaglutide and tirzepatide have exploded in popularity, with millions of Americans turning to them for weight loss. But are they the magic bullet for sustainable results? The ...
New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...
Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...
Weight-loss injections, or GLP-1 receptor agonists, could nearly halve the risk of obesity-related cancers, a new study finds ...
They mimic a hormone in the body, GLP-1, that lowers blood sugar levels and makes people ... First generation GLP-1s and ...
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...
David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback